 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Edwards Lifesciences Corporation (EW) provides products and technologies to treat structural heart disease and critically ill patients worldwide.
The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve.
In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings; minimally invasive continuous cardiac output monitoring systems and non invasive hemodynamic monitor for real time beat-to-beat information; pulmonary artery catheters; continuous venous oximetry catheter for measuring central venous oxygen saturation; and sensor-catheter sets that measures a critically ill patient's volumetric hemodynamic parameters.
Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors.
The firm is scheduled to report its earnings next week. Ahead of that, shares have found their 200-day moving average as a support (shown in green). Shares are heading higher in an upward trading channel (shown in blue). Higher share prices are expected for this stock.
52-Weeks Trading Range: $61.38 - $83.44
Entry Point: $75.30
Stop Loss: $71.50
Target Price: $82.85
EW closed at $83.00.
